IL1B and type 2 diabetes mellitus: According to the result from CANTOS trials, canakinumab (a fully humanized monoclonal antibody) could selectively block IL-1β, and its efficacy in suppressing both levels of inflammatory markers and clinical symptoms in patients with autoinflammatory disease such as T2DM and impaired glucose tolerance has been observed in this trial (Aday & Ridker, 2018; Rissanen et al., 2012).